Clin Endosc.  2018 Jul;51(4):344-351. 10.5946/ce.2018.099.

Quality Indicators in Barrett's Esophagus: Time to Change the Status Quo

• Han S
• Wani S

• KMID: 2419705
• DOI: http://doi.org/10.5946/ce.2018.099

Abstract

The push for high quality care in all fields of medicine highlights the importance of establishing and adhering to quality indicators. In response, several gastrointestinal societies have established quality indicators specific to Barrett's esophagus, which serve to create thresholds for performance while standardizing practice and guiding value-based care. Recent studies, however, have consistently demonstrated the lack of adherence to these quality indicators, particularly in surveillance (appropriate utilization of endoscopy and obtaining biopsies using the Seattle protocol) and endoscopic eradication therapy practices. These findings suggest that innovative interventions are needed to address these shortcomings in order to deliver high quality care to patients with Barrett's esophagus.

Keyword

Barrett's esophagus; Quality indicators

MeSH Terms

Barrett Esophagus*
Biopsy
Endoscopy
Humans

Reference

1. Fitzgerald RC, di Pietro M, Ragunath K, et al. British Society of Gastroenterology guidelines on the diagnosis and management of Barrett’s oesophagus. Gut. 2014; 63:7–42.

2. Wani S, Falk GW, Post J, et al. Risk factors for progression of low-grade dysplasia in patients with Barrett’s esophagus. Gastroenterology. 2011; 141:1179–1186. 1186.e1.

3. Thrift AP. Barrett’s esophagus and esophageal adenocarcinoma: how common are they really? Dig Dis Sci. 2018; 63:1988–1996.

4. Sharma P, Katzka DA, Gupta N, et al. Quality indicators for the management of Barrett’s esophagus, dysplasia, and esophageal adenocarcinoma: international consensus recommendations from the American Gastroenterological Association Symposium. Gastroenterology. 2015; 149:1599–1606.

5. Wani S, Muthusamy VR, Shaheen NJ, et al. Development of quality indicators for endoscopic eradication therapies in Barrett’s esophagus: the TREAT-BE (Treatment with Resection and Endoscopic Ablation Techniques for Barrett’s Esophagus) Consortium. Gastrointest Endosc. 2017; 86:1–17. e3.

6. Wani S, Muthusamy VR, Shaheen NJ, et al. Development of quality indicators for endoscopic eradication therapies in Barrett’s esophagus: the TREAT-BE (Treatment With Resection and Endoscopic Ablation Techniques for Barrett’s Esophagus) Consortium. Am J Gastroenterol. 2017; 112:1032–1048.

7. Institute of Medicine (US). America’s health in transition: protecting and improving quality. Washington, D.C.: National Academies Press (US);1994.

8. Rubenstein JH, Lieberman D, Fennerty B, Gellad ZF. Measuring the quality of Barrett’s esophagus management with measures that are high quality. Gastroenterology. 2015; 149:1298–1301.

9. Rizk MK, Sawhney MS, Cohen J, et al. Quality indicators common to all GI endoscopic procedures. Gastrointest Endosc. 2015; 81:3–16.

10. Sharma P, Dent J, Armstrong D, et al. The development and validation of an endoscopic grading system for Barrett’s esophagus: the Prague C & M criteria. Gastroenterology. 2006; 131:1392–1399.

11. Vogt JS, Larsen AC, Sommer T, Ejstrud P. Quality of endoscopic surveillance of Barrett’s esophagus. Scand J Gastroenterol. 2018; 53:256–259.

12. Han S, Yadlapati R, DeLay K, et al. Factors associated with suboptimal adherence to quality indicators in Barrett’s esophagus. Gastroenterology. 2018; 154(6 Suppl 1):S–140.

13. Ooi J, Wilson P, Walker G, et al. Dedicated Barrett’s surveillance sessions managed by trained endoscopists improve dysplasia detection rate. Endoscopy. 2017; 49:524–528.

14. Sharma P, Hawes RH, Bansal A, et al. Standard endoscopy with random biopsies versus narrow band imaging targeted biopsies in Barrett’s oesophagus: a prospective, international, randomised controlled trial. Gut. 2013; 62:15–21.

15. Shaheen NJ, Fennerty MB, Bergman JJ. Less is more: a minimalist approach to endoscopy. Gastroenterology. 2018; 154:1993–2003.

16. Wani SB, Williams JL, Komanduri S, Muthusamy VR, Shaheen NJ. Over-utilization of repeat upper endoscopy in patients with non-dysplastic Barrett’s esophagus: a population-based study using a national benchmarking registry. Gastroenterology. 2018; 154(6 Suppl 1):S28–S29.

17. Tavakkoli A, Appelman HD, Beer DG, et al. Use of appropriate surveillance for patients with nondysplastic Barrett’s esophagus. Clin Gastroenterol Hepatol. 2018; 16:862–869. e3.

18. Desai TK, Krishnan K, Samala N, et al. The incidence of oesophageal adenocarcinoma in non-dysplastic Barrett’s oesophagus: a meta-analysis. Gut. 2012; 61:970–976.

19. Abrams JA, Kapel RC, Lindberg GM, et al. Adherence to biopsy guidelines for Barrett’s esophagus surveillance in the community setting in the United States. Clin Gastroenterol Hepatol. 2009; 7:736–742. quiz 710.

20. Westerveld D, Khullar V, Mramba L, et al. Adherence to quality indicators and surveillance guidelines in the management of Barrett’s esophagus: a retrospective analysis. Endosc Int Open. 2018; 6:E300–E307.

21. Wani SB, Williams JL, Komanduri S, Muthusamy VR, Shaheen NJ. Endoscopists biopsy the least those who need it the most: an analysis of Barrett’s esophagus biopsy practices from a national quality benchmarking registry. Gastrointest Endosc. 2018; 87(6 Suppl):AB114.

22. Wani SB, William JL, Komanduri S, Muthusamy VR, Shaheen NJ. Regional variations and trends in quality indicator (QI) performance in Barrett’s esophagus (BE): results from a population-based study using a national benchmarking registry. Gastrointest Endosc. 2018; 87(6 Suppl):AB537.

23. Curvers WL, ten Kate FJ, Krishnadath KK, et al. Low-grade dysplasia in Barrett’s esophagus: overdiagnosed and underestimated. Am J Gastroenterol. 2010; 105:1523–1530.

24. Qumseya BJ, Wani S, Gendy S, Harnke B, Bergman JJ, Wolfsen H. Disease progression in Barrett’s low-grade dysplasia with radiofrequency ablation compared with surveillance: systematic review and meta-analysis. Am J Gastroenterol. 2017; 112:849–865.

25. Schölvinck DW, van der Meulen K, Bergman JJGHM, Weusten BLAM. Detection of lesions in dysplastic Barrett’s esophagus by community and expert endoscopists. Endoscopy. 2017; 49:113–120.

26. Moss A, Bourke MJ, Hourigan LF, et al. Endoscopic resection for Barrett’s high-grade dysplasia and early esophageal adenocarcinoma: an essential staging procedure with long-term therapeutic benefit. Am J Gastroenterol. 2010; 105:1276–1283.

27. Wani S, Mathur SC, Curvers WL, et al. Greater interobserver agreement by endoscopic mucosal resection than biopsy samples in Barrett’s dysplasia. Clin Gastroenterol Hepatol. 2010; 8:783–788.

28. Standards of Practice Committee, Wani S, Qumseya B, et al. Endoscopic eradication therapy for patients with Barrett’s esophagus-associated dysplasia and intramucosal cancer. Gastrointest Endosc. 2018; 87:907–931. e9.

29. Pech O, Behrens A, May A, et al. Long-term results and risk factor analysis for recurrence after curative endoscopic therapy in 349 patients with high-grade intraepithelial neoplasia and mucosal adenocarcinoma in Barrett’s oesophagus. Gut. 2008; 57:1200–1206.

30. Shaheen NJ, Sharma P, Overholt BF, et al. Radiofrequency ablation in Barrett’s esophagus with dysplasia. N Engl J Med. 2009; 360:2277–2288.

31. Phoa KN, van Vilsteren FG, Weusten BL, et al. Radiofrequency ablation vs endoscopic surveillance for patients with Barrett esophagus and low-grade dysplasia: a randomized clinical trial. JAMA. 2014; 311:1209–1217.

32. Cotton CC, Haidry R, Thrift AP, Lovat L, Shaheen NJ. Development of evidence based surveillance intervals following radiofrequency ablation of Barrett’s esophagus. Gastroenterology. 2018; Apr. 12. [Epub]. https://doi.org/10.1053/j.gastro.2018.04.011.

33. van Vilsteren FG, Alvarez Herrero L, Pouw RE, et al. Predictive factors for initial treatment response after circumferential radiofrequency ablation for Barrett’s esophagus with early neoplasia: a prospective multicenter study. Endoscopy. 2013; 45:516–525.

34. Komanduri S, Kahrilas PJ, Krishnan K, et al. Recurrence of Barrett’s esophagus is rare following endoscopic eradication therapy coupled with effective reflux control. Am J Gastroenterol. 2017; 112:556–566.

35. Qumseya BJ, Wani S, Desai M, et al. Adverse events after radiofrequency ablation in patients with Barrett’s esophagus: a systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2016; 14:1086–1095. e6.